Open framework agreement on pharmaceutical rebates pursuant to § 130a para. 8 SGB V with the possibility of joining at any time, so-called approval model 2025-01
Offene Rahmenvereinbarung über Arzneimittelrabatte gemäß § 130a Abs.8 SGB V mit jederzeitiger Beitrittsmöglichkeit, sog. Zulassungsmodell 2025-01
Germany · Bochum · how to bid here →
Your path to submission
- Deadline: 5 November at 23:59 — 30 days left.
- The submission point is stated in the notice (link on the right).
- Offer and evidence in: DEU, DEU, DEU, DEU, DEU, DEU, DEU, DEU, DEU, DEU, DEU, DEU, DEU, DEU, DEU.
- Collect your evidence — use the eligibility analysis above: it lists the requirements and, for known certificates, how to get them.
Clement What the numbers say about this buyer
- In this sector the buyer awards roughly every month (323 awards, most recently June 2026) — by that rhythm the next award was due around July 2026. The last award went to Pharmazeutische Unternehmen.n = 323
- 49% of this buyer's awards went to companies that had already won here before (560 awards since 2018, spread over 286 companies). That is well below the sector norm (62%) — this buyer switches suppliers more often than others.n = 560 awards since 2018
- The award came in at a median 67% of the estimated value (5 awards with both estimate and value) — pricing at the estimate is usually too high here. Sector: 87%.n = 5
- The median procedure drew just one bid (537 procedures with a bid count); 67% ended with a single bidder. Sector: median 2 bids.n = 537
- Across 65 procedures with structured selection criteria, this buyer most often required: Quality management (63 of 65), Trade register enrolment (63 of 65), References: services (2 of 65).n = 65
From this buyer's documented awards; comparison values from the same sector and country. Not a forecast, not legal advice. As of 04/10/2026.
Foreign bidders
In Germany · Medical equipment & pharma, 265 contracts went to foreign companies over the last 3 years (of 22,200 recorded awards) — mostly from Austria, Netherlands, France.
Submission language: DEU.
Typical field: median 41 (from 962 awards).
What the buyer is looking for
This Notice is intended to conclude agreements on the active substance ‘Bexarotene, (ATC code: L01XF03)’ with pharmaceutical companies within the meaning of Section 130a(8), first sentence, of the Social Code, Book 5 (SGB V) (discount contracts). Pursuant to the first sentence of Paragraph 130a(8) of the SGB V, the invitation to participate is addressed only to pharmaceutical entrepreneurs or groups of employees of pharmaceutical entrepreneurs within the meaning of Paragraph 4(18) of the Arzneimittelgesetz (AMG). It is not an open procedure, but a publication of the invitation to conclude/join/discount contracts with conditions fixed and non-negotiable for all participants, including the amount of the discount. The corresponding information under point 2.1 "Type of procedure" and under point 5.1.12 "Condition for procurement _ here: The time limit by which the tender must be valid" is…
Show full description
… only due to the general scheme of this form. Contractual partners can become an unlimited number of pharmaceutical entrepreneurs or employee groups of pharmaceutical entrepreneurs within the meaning of Section 4(18) of the German Medicines Act (AMG). The contract is concluded or acceded to by completing the required self-declarations or supporting documents as well as the contract(s) either: a) Handwritten signature (written form according to § 126 BGB) by post or b) With a qualified electronic signature (§ 126a BGB) provided by e-mail to [email protected] to be sent to KBS. The earliest start date of the contract is 01.01.2025, provided that the contract and the required declarations or evidence have been received by KBS by 05.12.2024 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or proofs by the KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the following month. Contracts shall terminate automatically, without any need for termination, as soon as the active substance(s) or combination(s) of active substance(s) have been contracted through a formal procurement procedure. The deadline for the receipt of accessions is 05.11.2026. In any case, the contracts end on 31.12.2026. · The purpose of this notice is to conclude agreements on the active substance certolizumab (ATC code: L04AB05)’ with pharmaceutical companies within the meaning of Section 130a(8), first sentence, of the Social Code, Book 5 (SGB V) (discount contracts). Pursuant to the first sentence of Paragraph 130a(8) of the SGB V, the invitation to participate is addressed only to pharmaceutical entrepreneurs or groups of employees of pharmaceutical entrepreneurs within the meaning of Paragraph 4(18) of the Arzneimittelgesetz (AMG). It is not an open procedure, but a publication of the invitation to conclude/join/discount contracts with conditions fixed and non-negotiable for all participants, including the amount of the discount. The corresponding information under point 2.1 "Type of procedure" and under point 5.1.12 "Condition for procurement _ here: The time limit by which the tender must be valid" is only due to the general scheme of this form. Contractual partners can become an unlimited number of pharmaceutical entrepreneurs or employee groups of pharmaceutical entrepreneurs within the meaning of Section 4(18) of the German Medicines Act (AMG). The contract is concluded or acceded to by completing the required self-declarations or supporting documents as well as the contract(s) either: a) Handwritten signature (written form according to § 126 BGB) by post or b) With a qualified electronic signature (§ 126a BGB) provided by e-mail to [email protected] to be sent to KBS. The earliest start date for the contract is 01.01.2025, provided that the contract and the required declarations or evidence have been received by KBS by 05.12.2024 at the latest.
What you must prove — eligibility criteria
Contract
Who has won here before
| Company | Awards | Period |
|---|---|---|
| Aliud Pharma GmbH · Laichingen | 26 | 2012–2023 |
| Aristo Pharma GmbH · Berlin | 26 | 2012–2022 |
| Hexal AG · Holzkirchen | 20 | 2012–2023 |
| Glenmark Arzneimittel GmbH · Gröbenzell | 14 | 2012–2023 |
| ratiopharm GmbH | 13 | 2014–2023 |
How often this buyer tenders this
Who knows the rhythm prepares instead of reacting.